{"filing":{"accession_number":"0001730430-26-000031","cik":"0001730430","ticker":"KNSA","company_name":"Kiniksa Pharmaceuticals International, plc","form":"8-K","filing_date":"2026-07-28","report_date":"2026-07-28","primary_document":"knsa-20260728x8k.htm","primary_document_url":"https://www.sec.gov/Archives/edgar/data/1730430/000173043026000031/knsa-20260728x8k.htm"},"events":[{"id":20907,"run_id":18827,"accession_number":"0001730430-26-000031","anchor_item_number":"2.02","event_type":"earnings_release","event_domain":"financial","is_material":true,"confidence":0.98,"summary":"This is a clear earnings release for Q2 2026 financial results. The Item 2.02 disclosure states \"Kiniksa Pharmaceuticals International, plc issued a press release announcing financial results for the quarter ended June 30, 2026,\" and the attached exhibit (EX-99.1) is the full press release reporting Q2 2026 financial results including total revenue of $243.6 million, operating expenses of $216.4 million, and net income of $25.4 million, along with updated 2026 ARCALYST revenue guidance of $980-$995 million. This is material to investors as it discloses quarterly financial performance and updated full-year guidance.","company_name":"Kiniksa Pharmaceuticals International, plc","ticker":"KNSA","filing_date":"2026-07-28","form":"8-K","submitted_at":null,"items":[{"id":20411,"accession_number":"0001730430-26-000031","item_number":"2.02","item_title":"Results of Operations and Financial Condition","event_type":"earnings_release","event_domain":"financial","is_material":true,"confidence":0.98,"reasoning":"This is a clear earnings release for Q2 2026 financial results. The Item 2.02 disclosure states \"Kiniksa Pharmaceuticals International, plc issued a press release announcing financial results for the quarter ended June 30, 2026,\" and the attached exhibit (EX-99.1) is the full press release reporting Q2 2026 financial results including total revenue of $243.6 million, operating expenses of $216.4 million, and net income of $25.4 million, along with updated 2026 ARCALYST revenue guidance of $980-$995 million. This is material to investors as it discloses quarterly financial performance and updated full-year guidance.","classifier_version":"claude-haiku-4-5-20251001+prompt-a85dd512","taxonomy_version":"v1.3","classified_at":"2026-07-28T11:34:39.642407+00:00","company_name":"","ticker":null,"filing_date":""}]}],"classifications":[{"id":20411,"accession_number":"0001730430-26-000031","item_number":"2.02","item_title":"Results of Operations and Financial Condition","event_type":"earnings_release","event_domain":"financial","is_material":true,"confidence":0.98,"reasoning":"This is a clear earnings release for Q2 2026 financial results. The Item 2.02 disclosure states \"Kiniksa Pharmaceuticals International, plc issued a press release announcing financial results for the quarter ended June 30, 2026,\" and the attached exhibit (EX-99.1) is the full press release reporting Q2 2026 financial results including total revenue of $243.6 million, operating expenses of $216.4 million, and net income of $25.4 million, along with updated 2026 ARCALYST revenue guidance of $980-$995 million. This is material to investors as it discloses quarterly financial performance and updated full-year guidance.","classifier_version":"claude-haiku-4-5-20251001+prompt-a85dd512","taxonomy_version":"v1.3","classified_at":"2026-07-28T11:34:39.642407+00:00","company_name":"Kiniksa Pharmaceuticals International, plc","ticker":"KNSA","filing_date":"2026-07-28"}]}